Gastroesophageal Reflux

Oncology·MeSH: Gastroesophageal Reflux

Prevalence

10903.8 / 100K

Incidence

4267.4 / 100K/yr

15 drugs in development·10 companies·3 clinical trials

Drug Pipeline by Phase

Approved(11)

Drug	Company
dexlansoprazole	Mylan II B.V. (MYL)
famotidine	ENGENE HOLDINGS INC. (ENGN)
famotidine	Seagen Inc. (SGEN)
famotidine	SUNSET ISLAND GROUP (SUN)
famotidine	Miromatrix Medical Inc. (MIRO)
famotidine	Mersana Therapeutics, Inc. (MRSN)
famotidine	Avita Medical Inc. (RCEL)
inFoods® (IBS)	BIOMERICA INC (BMRA)
pantoprazole	EXELIXIS, INC. (EXEL)
pantoprazole	SUNSET ISLAND GROUP (SUN)
VOQUEZNA	Phathom Pharmaceuticals, Inc. (PHAT)

Phase 3(4)

Drug	Company
Vonoprazan	Phathom Pharmaceuticals, Inc. (PHAT)
vonoprazan (VOQUEZNA)	Phathom Pharmaceuticals, Inc. (PHAT)
vonoprazan (VOQUEZNA) - as-needed regimen	Phathom Pharmaceuticals, Inc. (PHAT)
vonoprazan (VOQUEZNA) - EoE	Phathom Pharmaceuticals, Inc. (PHAT)

BioSniper tracks 15 drugs in development for Gastroesophageal Reflux across 10 companies.

There are 3 clinical trials targeting Gastroesophageal Reflux tracked by BioSniper.

The estimated prevalence of Gastroesophageal Reflux is approximately 10903.8 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.